Molecular and Vascular MRI of Placenta Accreta
Molecular and Vascular MRI of Placenta Accreta
批准号:
10364608
负责人:
Ananth V Annapragada
金额:
$37.17万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-16 至 2024-01-31
关键词:
AcidsAddressAdmission activityAmyloidAwardBindingBlood VesselsCellsCesarean sectionChelating AgentsClinicalComplexContrast MediaDataDefectDepositionDetectionDiagnosisEarly DiagnosisEmbryoExhibitsExposure toFetal GrowthFetal safetyFrightGadoliniumGene ExpressionGestational AgeGrowthHemorrhageHistologicHumanHysterectomyImageImmunohistochemistryIncidenceKnockout MiceLiposomesMagnetic Resonance ImagingMeasuresMethodologyModelingMolecularMolecular TargetMyometrialNational Institute of Child Health and Human DevelopmentNephrogenic Systemic FibrosisNulliparityPaperPediatric RadiologyPlacentaPlacenta AccretaPlacentationPopulationPopulation StudyPregnancyPreparationRAMP2RattusRecording of previous eventsReportingRestRiskRisk FactorsRodent ModelSafetySecond Pregnancy TrimesterSenile PlaquesSensitivity and SpecificitySocietiesStructureTechnologyTestingThird Pregnancy TrimesterTimeToxic effectToxicologyUterusVariantVisualizationWomanadrenomedullinadrenomedullin receptorbasecontrast enhanceddiagnostic accuracyfetalfolate-binding proteinimaging agentimaging modalityimplantationinterfacialmaternal safetymeetingsmolecular imagingnovelparticlepre-clinicalprenatal exposurereceptorresponsetechnology developmenttooltrophoblastultrasound
中文摘要
我们提出了一种基于脂质体MRI成像剂的新平台技术,
胎盘的血管和分子成像。 我们专注于这种应用病态粘连胎盘
(MAP:分类为胎盘植入,植入或percreta),并将展示这项技术的力量,
研究这种情况,注意到这项技术一旦开发出来,将适用于许多其他胎盘
条件 MAP的诊断仍然具有挑战性,即使在不确定的情况下进行超声和MRI:仅
大约一半的MAP病例是在分娩前被怀疑的15。 MAP导致大量失血(25%的病例),
子宫切除术(70%的病例)和ICU入院(30%的病例),比率远高于非ESTA-MAP人群。
胎盘后间隙的检测是正常胎盘形成的标志。 此外,
肾上腺髓质素及其受体(CRP 17/RAMP 2复合物)被认为是MAP的早期标志物。具体目标
因此,该项目
1.在啮齿动物模型中,用脂质体Gd造影剂定量胎盘边缘勾画。
a.检查“胎盘后间隙”的可视化,这是胎盘与胎盘之间的一个血管化不良的层。
胎盘和子宫肌层壁,作为边缘描绘的量度,作为胎龄的函数。
B.比较非增强MRI对胎盘后间隙和胎盘边缘的检测,
传统的Gd螯合物,通过怀孕的过程。
2.检测胎盘和子宫中肾上腺髓质素受体(CRYP 3/RAMP 2)的空间表达是否与胎盘和子宫内膜中CRYP 3/RAMP 2的表达有关。
在一定的胎龄范围内,胎盘壁与胎盘浸润相关。
a.使用肾上腺髓质素靶向Gd脂质体,通过MRI可视化和定量CRP 4/RAMP 2,以及
使用免疫组织化学验证
B.将CRYST/RAMP 2水平与基于影像学的边缘勾画和组织学确定的
整个妊娠期胎盘侵入。
英文摘要
We propose a novel platform technology based on liposomal MRI imaging agents that provide methodology for safe,
facile vascular and molecular imaging of the placenta. We focus in this application on Morbidly Adherent Placenta
(MAP: classified as placenta accreta, increta or percreta), and will demonstrate the power of this technology for the
study of this condition, noting that the technology once developed will be applicable to numerous other placental
conditions. Diagnosis of MAP remains challenging, even with ultrasound followed by MRI in indeterminate cases: only
about half of the cases of MAP are suspected prior to childbirth15. MAP results in massive blood loss (25% of cases),
hysterectomy (70% of cases) and ICU admission (30% of cases), at rates far higher than the non-‐MAP population.
The detection of a “retroplacental clear space” is a marker of normal placentation. Further, the level of
adrenomedullin and its receptor (the CRCLR/RAMP2 complex) is thought to be an early marker of MAP. The specific aims
of this project are therefore
1. Quantify placental margin delineation with the liposomal Gd contrast agent, in rodent models.
a. Test the visualization of the “retroplacental clear space”, a poorly vascularized layer between the
placenta and the myometrial wall, as a measure of margin delineation, as a function of gestational age.
b. Compare detection of the retroplacental clear space and placental margins with non-‐contrast MRI and
conventional Gd chelates, through the course of gestation.
2. Test whether the spatial expression of the Adrenomedullin receptor (CRCLR/RAMP2) in the placenta and uterine
wall correlate with placental invasion, across a range of gestational ages.
a. Visualize and quantify CRCLR/RAMP2 with MRI using an adrenomedullin targeted Gd liposome, and
validate using immunohistochemistry
b. Correlate CRCLR/RAMP2 levels with imaging based margin delineation and histologically determined
placental invasion throughout gestation.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.ajog.2020.01.044
发表时间:
2020-09
期刊:
American journal of obstetrics and gynecology
影响因子:
9.8
作者:
[Kingdom JC, Hobson SR, Murji A, Allen L, Windrim RC, Lockhart E, Collins SL, Soleymani Majd H, Alazzam M, Naaisa F, Shamshirsaz AA, Belfort MA, Fox KA]
通讯作者:
Fox KA
A Hyperfluorinated Hydrophilic Molecule for Aqueous 19F MRI Contrast Media.
用于水性 19F MRI 造影剂的高氟化亲水分子。
DOI:
10.1155/2018/1693513
发表时间:
2018
期刊:
Contrast media & molecular imaging
影响因子:
--
作者:
[Tanifum,EricA, Devkota,Laxman, Ngwa,Conelius, Badachhape,AndrewA, Ghaghada,KetanB, Romero,Jonathan, Pautler,RobiaG, Annapragada,AnanthV]
通讯作者:
Annapragada,AnanthV
Nanoprobes for Computed Tomography and Magnetic Resonance Imaging in Atherosclerosis Research.
用于动脉粥样硬化研究中计算机断层扫描和磁共振成像的纳米探针。
DOI:
10.1007/978-1-0716-1924-7_49
发表时间:
2022
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Ghaghada,KetanB, Bhavane,Rohan, Badachhape,Andrew, Tanifum,Eric, Annapragada,Ananth]
通讯作者:
Annapragada,Ananth
DOI:
10.1007/s10237-021-01495-9
发表时间:
2021-12
期刊:
Biomechanics and modeling in mechanobiology
影响因子:
3.5
作者:
[Hossain SS, Starosolski Z, Sanders T, Johnson MJ, Wu MCH, Hsu MC, Milewicz DM, Annapragada A]
通讯作者:
Annapragada A
DOI:
10.1016/j.ajog.2019.05.035
发表时间:
2019-10
期刊:
American journal of obstetrics and gynecology
影响因子:
9.8
作者:
[Erfani H, Fox KA, Clark SL, Rac M, Rocky Hui SK, Rezaei A, Aalipour S, Shamshirsaz AA, Nassr AA, Salmanian B, Stewart KA, Kravitz ES, Eppes C, Coburn M, Espinoza J, Teruya J, Belfort MA, Shamshirsaz AA]
通讯作者:
Shamshirsaz AA
共 7 条
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
-
批准号:10595710
-
项目类别:
-
资助金额:$2.1万
-
财政年份:2022
-
负责人:Ananth V Annapragada
-
依托单位:
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
-
批准号:10456621
-
项目类别:
-
资助金额:$66.1万
-
财政年份:2020
-
负责人:Ananth V Annapragada
-
依托单位:
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
-
批准号:10291087
-
项目类别:
-
资助金额:$76.17万
-
财政年份:2020
-
负责人:Ananth V Annapragada
-
依托单位:
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
-
批准号:10302326
-
项目类别:
-
资助金额:$74.53万
-
财政年份:2020
-
负责人:Ananth V Annapragada
-
依托单位:
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
-
批准号:10675212
-
项目类别:
-
资助金额:$6.42万
-
财政年份:2020
-
负责人:Ananth V Annapragada
-
依托单位:
Aptamer mediated targeting of Fanconi Anemia oral cancer initiating cells
-
批准号:8722234
-
项目类别:
-
资助金额:$39.65万
-
财政年份:2014
-
负责人:Ananth V Annapragada
-
依托单位:
Aptamer mediated targeting of Fanconi Anemia oral cancer initiating cells
-
批准号:8896720
-
项目类别:
-
资助金额:$38.36万
-
财政年份:2014
-
负责人:Ananth V Annapragada
-
依托单位:
Aptamer mediated targeting of Fanconi Anemia oral cancer initiating cells
-
批准号:9060921
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2014
-
负责人:Ananth V Annapragada
-
依托单位:
海外基金